Paraneoplastic disorders

CONTINUUM Lifelong Learning in Neurology

Volumn 21, Issue 2, 2015, Pages 452-475

  Lancaster, Eric ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; AMPA RECEPTOR; AMPHIPHYSIN; AUTOANTIBODY; DOPAMINE 2 RECEPTOR; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; GLYCINE RECEPTOR; HU PROTEIN; IMMUNOMODULATING AGENT; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE PROTEIN; PROTEIN HOMER 3; VOLTAGE GATED POTASSIUM CHANNEL; DNA BINDING PROTEIN; GLUTAMATE DECARBOXYLASE; MEMBRANE PROTEIN;

ANTIBODY TITER; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; CANCER RISK; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; HUMAN; IMMUNOTHERAPY; MORVAN SYNDROME; MYASTHENIA GRAVIS; MYOKYMIA; NEUROLOGIST; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; PERIPHERAL NERVOUS SYSTEM; PROGRESSIVE ENCEPHALOMYELITIS WITH RIGIDITY AND MYOCLONUS; REVIEW; STIFF MAN SYNDROME; SYNAPSE; T LYMPHOCYTE; TREATMENT RESPONSE; COMPLICATION; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; NEOPLASMS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; PROCEDURES; RISK FACTOR;

AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; DNA-BINDING PROTEINS; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; MYASTHENIA GRAVIS; NEOPLASMS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS;

EID: 84926434886     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000464180.89580.88     Document Type: Review

References (38)

1. Marx A, Pfister F, Schalke B, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013;12(9): 875-884. doi:10. 1016/j. autrev. 2013. 03. 007.
2. Vernino S, Lennon VA. Neuronal ganglionic acetylcholine receptor autoimmunity. Ann N Y Acad Sci 2003;998:211-214. doi:10. 1196/annals. 1254. 023.
3. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10(12):1098-1107. doi:10. 1016/S1474-4422(11)70245-9.
4. Burk K, Wick M, Roth G, et al. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol 2010;257(1):59-62. doi:10. 1007/s00415-009-5262-8.
5. European Federation of Neurological Societies; Peripheral Nerve Society, Hadden RD, Nobile-Orazio E, Sommer C, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13(8):809-818. doi:10. 1111/j. 1468-1331. 2006. 01467. x.
6. Andras C, Ponyi A, Constantin T, et al. Dermatomyositis and polymyositis associated with malignancy: A 21-year retrospective study. J Rheumatol 2008;35(3):438-444.
7. Arin o H, Gresa-Arribas N, Blanco Y, et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies immunologic profile and long-termeffect of immunotherapy. JAMA Neurol 2014;71(8):1009-1016. doi:10. 1001/jamaneurol. 2014. 1011.
8. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 2005;58(1): 96-107. doi:10. 1002/ana. 20529.
9. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012;72(2):241-255. doi:10. 1002/ana. 23577.
10. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: Analysis of 200 patients. Brain 2001;124(pt 6):1138-1148. doi:10. 1093/brain/124. 6. 1138.
11. Hoffmann LA, Jarius S, Pellkofer HL, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008;79(7):767-773. doi:10. 1136/jnnp. 2007. 118588.
12. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004;127(pt 8):1831-1844. doi:10. 1093/brain/awh203.
13. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992;42(10):1931-1937. doi:10. 1212/WNL. 42. 10. 1931.
14. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003;53(5):580-587. doi:10. 1002/ana. 10518.
15. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009;80(4): 412-416. doi:1136/jnnp. 2007. 138016.
16. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000;47(3):297-305. doi:10. 1002/1531-8249(200003)47:3G297: AID-ANA493. 0. CO;2-4.
17. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001;50(3):301-311. doi:10. 1002/ana. 1127.
18. Pittock SJ, Yoshikawa H, Ahlskog JE, et al. Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction. Mayo Clin Proc 2006;81(9): 1207-1214. doi:10. 4065/81. 9. 1207.
19. Burton AR, Baquet Z, Eisenbarth GS, et al. Central nervous system destruction mediated by glutamic acid decarboxylase-specific CD4+ T cells. J Immunol 2010;184(9):4863-4870. doi:10. 4049/jimmunol. 0903728.
20. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10(1):63-74. doi:10. 1016/S1474-4422(10)70253-2.
21. Moscato EH, Jain A, Peng X, et al. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. Eur J Neurosci 2010;32(2):298-309. doi:10. 1111/j. 1460-9568. 2010. 07349. x.
22. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009;65(4):424-434. doi:10. 1002/ana. 21589.
23. Gleichman AJ, Panzer JA, Baumann BH, et al. Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis. Ann Clin Transl Neurol 2014;1(1):180-189. doi:10. 1002/acn3. 43.
24. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010;133(9): 2734-2748. doi:10. 1093/brain/awq213.
25. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic previously attributed to potassium channels: A case series. Lancet Neurol 2010;9(8):776-785. doi:10. 1016/S1474-4422(10)70137-X.
26. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013;33(46): 18161-18174. doi:10. 1523/JNEUROSCI. 3506-13. 2013.
27. Hoftberger R, Titulaer MJ, Sabater L, et al. Encephalitis and GABAB receptor antibodies: Novel findings in a new case series of 20 patients. Neurology 2013;81(17): 1500-1506. doi:10. 1212/WNL. 0b013e3182a9585f.
28. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: A case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13(3):276-286. doi:10. 1016/S1474-4422(13)70299-0.
29. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011;77(18):1698-1701. doi:10. 1212/WNL. 0b013e3182364a44.
30. Coesmans M, Smitt PA, Linden DJ, et al. Mechanisms underlying cerebellarmotor deficits due to mGluR1-autoantibodies. Ann Neurol 2003;53(3):325-336. doi:10. 1002/ana. 10451.
31. Zuliani L, Sabater L, Saiz A, et al. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology 2007;68(3): 239-240. doi:10. 1212/01. wnl. 0000251308. 79366. f9.
32. Hoftberger R, Sabater L, Ortega A, et al. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol 2013;70(4): 506-509. doi:10. 1001/jamaneurol. 2013. 1955.
33. de Graaff E, Maat P, Hulsenboom E, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol 2012;71(6): 815-824. doi:10. 1002/ana. 23550.
34. Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain 2012;135(pt 11):3453-3468. doi:10. 1093/brain/aws256.
35. Cox CJ, Sharma M, Leckman JF, et al. Brain human monoclonal autoantibody from Sydenham chorea targets dopaminergic neurons in transgenic mice and signals dopamine D2 receptor: implications in human disease. J Immunol 2013; 191(11):5524-5541. doi:10. 4049/jimmunol. 1102592.
36. Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: A novel glycine receptor antibody. Neurology 2008;71(16):1291-1292. doi:10. 1212/01. wnl. 0000327606. 50322. f0.
37. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis. J Womens Health (Larchmt) 2009;18(3): 311-319. doi:10. 1089/jwh. 2008. 0857.
38. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study. Lancet Neurol 2014;13(2):167-177. doi:10. 1016/S1474-4422(13)70282-5.